The short version of counter-ion fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-04 and is reviewed periodically as new material appears.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Storage of dry powder | -20 °C or below | Common practice for long-term retention |
| Storage after reconstitution | 2-8 °C, short term | Solution stability is limited compared with dry powder |
| Typical analytical method | Reversed-phase HPLC | Usually paired with mass spectrometry for mass confirmation |
| Detection wavelength | About 214 nm | Peptide backbone absorbance; buffer background must be controlled |
| Counter-ion forms | Acetate or trifluoroacetate | Affects mass balance and reported concentration |
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
== Computational and data analytical methods == Analysing AMR data at scale requires dedicated computational approaches, as routine microbiological data from clinical laboratories can be large, heterogeneous, and subject to varying local standards. Several open-source tools have been developed to support this work. The AMR package for R provides functions for standardising and analysing phenotypical resistance data, including interpretation of MIC and disk diffusion results against EUCAST and CLSI breakpoints, and calculation of resistance rates across patient populations.
==== Other skin conditions ==== Some types of phototherapy may be effective in the treatment of polymorphous light eruption, cutaneous T-cell lymphoma and lichen planus. Narrowband UVB between 311 and 313 nanometers is the most common treatment.
=== Post-processing === In the post-processing phase, printed food may require additional steps before consumption. This includes processing activities such as baking, frying, cleaning, etc. This phase can be one of the most critical to 3D printed food, as the printed food needs to be safe for consumption. An additional concern in post processing is the deformation of the printed food due to the strain of these additional processes. Current methods involve trial and error. That is, combining food additives with the materials/ingredients to improve the integrity of complex structures and to ensure the printed structure retains its shape. Additives such as transglutaminase and hydrocolloids have been added to ingredients in order to help retain the printed shape while printing and after cooking. Additionally, recent research has produced a visual simulation for baking breads, cookies, pancakes and similar materials that consist of dough or batter (mixtures of water, flour, eggs, fat, sugar and leavening agents). By adjusting certain parameters in the simulation, it shows the realistic effect that baking will have on the food. With further research and development, a visual simulation of 3D printed foods being cooked could predict what is vulnerable to deformation.
Sources: en.wikipedia.org
=== P4 medicine === Since 2002 Hood has progressively expanded his vision of the future of medicine: first focusing on predictive and preventive (2P) Medicine; then predictive, preventive and personalized (3P) Medicine; and finally predictive, preventive, personalized and participatory, also known as P4 Medicine. Hood states that P4 Medicine is the convergence of systems medicine, big data and patient (consumer) driven healthcare and social networks. Hood envisions that by the mid-2020s each individual will be surrounded by a virtual cloud of billions of data points and will have the computational tools to analyze this data and produce simple approaches to optimize wellness and minimize disease for each individual. According to this view, the patient's demand for better healthcare will be the real driving force for the acceptance of P4 Medicine by the medical community. This driving force is exemplified by the movement known as the quantified self, which uses digital devices to monitor self-parameters such as weight, activity, sleep, diet, etc. His view is that P4 Medicine will transform the practice of medicine over the next decade, moving it from a largely reactive, disease-care approach to a proactive P4 approach that is predictive, preventive, personalized and participatory. In 2010, Hood co-founded the P4 Medicine institute (P4Mi), for the development of Predictive, Preventive, Personalized and Participatory (P4) Medicine. In 2021 Hood founded Phenome Health, a non profit focused on implementing his vision.
== Discovery == The protein was first isolated in 1987 by Thomas J. Martin's team at the University of Melbourne. Miao et al. showed that disruption of the PTHrP gene in mice caused a lethal phenotype and distinct bone abnormalities, suggesting that PTHrP has a physiological function.
=== Primary sources === Cross, J. P., and Buddhiman Gurung, eds. Gurkhas at War in Their Own Words: The Gurkha Experience 1939 to the Present (London: Greenhill, 2002), Masters, John (1956). Bugles and a Tiger: Viking. (autobiographical account of his service as a junior British officer in a Gurkha regiment in the years leading up to World War II) Omissi, David E. ed. Indian Voices of the Great War: Soldiers' Letters, 1914–18 (1999) Francis J Short. Stories from the British Indian Army (2015)
An independent 2024 assembly of the same strain using a new technique (PacBio HiFi) produced an extra 4.17 million base pairs total and 8.0 million base pairs on chromosome arms. In 2024, a near-complete "telomere-to-telomere" genome assembly was produced for D. melanogaster strain Canton S, closing 93.28% of gaps in the release 6 genome. This was enabled by a combination of PacBio HiFi, Oxford Nanopore ultra-long reads, and Hi-C data. It measured 161.63 million base pairs, though a lot of the increase relative to reference appear to reflect actual strain-to-strain variation (and not an error in the R6 genome). D. melanogaster originated in sub-Saharan Africa and populations diverged as the species expanded across the globe. As of 2024, there are more than 1439 genome sequences representing the global diversity of this species, allowing for a detailed estimate of its global evolutionary history.
Sources: en.wikipedia.org
=== Cancer therapy === In magnetic fluid hyperthermia, nanoparticles of different types like Iron oxide, magnetite, maghemite or even gold are injected in tumor and then subjected under a high frequency magnetic field. These nanoparticles produce heat that typically increases tumor temperature to 40-46 °C, which can kill cancer cells. Another major potential of magnetic nanoparticles is the ability to combine heat (hyperthermia) and drug release for a cancer treatment. Numerous studies have shown particle constructs that can be loaded with a drug cargo and magnetic nanoparticles. The most prevalent construct is the "Magnetoliposome", which is a liposome with magnetic nanoparticles typically embedded in the lipid bilayer. Under an alternating magnetic field, the magnetic nanoparticles are heated, and this heat permeabilizes the membrane. This causes release of the loaded drug. This treatment option has a lot of potential as the combination of hyperthermia and drug release is likely to treat tumors better than either option alone, but it is still under development.
A κ-opioid receptor agonist, or simply KOR agonist or kappa agonist, is a drug which acts as an agonist of the κ-opioid receptor (KOR), the target of the endogenous dynorphin peptides such as dynorphin A and one of several types of opioid receptors. They can variably produce hallucinogenic effects, pro-depressive and dysphoric effects, sedation, analgesic effects, antipruritic (anti-itch) effects, and anti-addictive effects, among others. Due to their various effects, KOR agonists are used for a variety of medical uses and for other purposes. Salvinorin A is a highly potent and selective KOR agonist and hallucinogen found in Salvia divinorum (diviner's sage) which has been used as an entheogen by the Mazatec people of Mexico and as a recreational drug elsewhere. The psychoactive and other effects of salvinorin A have been evaluated in clinical studies. The non-selective opioid receptor antagonist naltrexone blocks the effects of salvinorin A. Synthetic analogues with greater potency and/or duration include salvinorin B methoxymethyl ether (2-MMSB) and salvinorin B ethoxymethyl ether (2-EMSB). The irreversible G protein-biased agonist RB-64 (22-thiocyanatosalvinorin A) has unknown psychoactivity. Nalorphine (N-allylnormorphine; Lethidrone; Nalline) was an early opioid antagonist used to reverse opioid overdose which acts as a dual μ-opioid receptor (MOR) agonist–antagonist and KOR agonist and was superseded by other drugs like naloxone due to producing dysphoria and hallucinogenic effects among other drawbacks.
=== Approval rate === While over 150 cerebroprotectants have been tested in clinical trials, as of 2022 only the above two cerebroprotectants are approved, though several clinical trials for other drugs are ongoing. The approval rate has been less than 2%, which is low compared to the overall approval rate of all drugs brought into clinical trials in all disease areas from 2011 to 2022 which was 7.9%. It is also much lower than the relatively high success rate for devices to treat acute ischemic stroke, as there have been at least 5 different clot removal devices approved since 2015.
Resmetirom, a liver-directed thyroid hormone receptor beta-selective agonist, was conditionally approved for medical use in the United States in March 2024 for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced fibrosis. Resmetirom was associated with increased rates of MASH resolution or regression of fibrosis, it also improved lipid levels. In August 2025, the US Food and Drug Administration expanded the indication for semaglutide to include the treatment of metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis (excessive scar tissue in the liver). Semaglutide was associated with MASH resolution in a 72-week trial compared to placebo. The percentage of people with MASH resolution was 32.7% (compared to 16% with placebo). Semaglutide may also cause regression of liver fibrosis to a less severe stage. Another trial showed that 63% of people had complete resolution of MASH, and 36.8% had at least 1 level of regression to a less severe stage of liver fibrosis. Semaglutide was also associated with a 13% weight loss in trials of MASH and improvements of some metabolic factors (such as the hemoglobin A1c (sugar levels)) which are protective in both MASLD and MASH.
=== Advantages and disadvantages === There is a wide variety of biological insecticides with differing attributes, but in general the following has been described. They are easier, faster and cheaper to register, usually with lower mammalian toxicity. They are more specific, and thus preserve beneficial insects and biodiversity in general. This makes them compatible with IPM regimes. They degrade rapidly causing less impact on the environment. They have a shorter withholding period. The spectrum of control is narrow. They are less effective and prone to adverse ambient conditions. They degrade rapidly and are thus less persistent. They are slower to act. They are more expensive, have a shorter shelf-life, and are more difficult to source. They require more specialised knowledge to use.
Sources: en.wikipedia.org
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.